Clinical trials: Tuberculosis Active
Tuberculosis, HIV Infections
TB (Tuberculosis) Preventive Therapy for HIV Patients With Access to HAART (Highly Active Antiretroviral Therapy)
The purpose of this study is to determine if implementing a policy of widespread INH (Isoniazid) prophylaxis therapy in HIV-infected patients with access to antiretroviral therapy reduces the incidence of active TB disease in the…
- Trial name
- NCT00107887
- Testing
- INH preventive therapy, TST (tuberculin skin test)
- Where
- Brazil
- Volunteers
- 17,415 people
- Sponsor
- Johns Hopkins University
Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis
A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets
This is a multicenter, randomized, open-label, active-controlled clinical study designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of different doses of JDB0131 benzenesulfonate tablets compared with…
- Conditions
- Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
- Trial name
- NCT07170800
- Testing
- JDB0131 100mg, JDB0131 200mg, Delamanid (D)
- Where
- 7 sites in China
- Volunteers
- 60 people
- Sponsor
- WestVac Biopharma Co., Ltd.
Tuberculosis
Nyaditum Resae® as a Co-adjuvant During Treatment for Active Pulmonary Tuberculosis and Its Impact on the Gut Microbiota
This will be the first study to evaluate the use of Nyaditum resae® as a potential agent for reducing antibiotic-associated gut dysbiosis in patients with drug-susceptible TB, and potentially improving clinical and…
- Trial name
- NCT03851159
- Testing
- Nyaditum resae®, Mannitol
- Where
- 2 sites in South Africa
- Volunteers
- 48 people
- Sponsor
- University of Stellenbosch
Tuberculosis
TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).
The objective of this study is to demonstrate that the antibacterial activity of TMC207 is better than placebo when added to a standardized Background Regimen (BR) for treatment of multi-drug resistant TB.
- Trial name
- NCT00449644
- Testing
- TMC207, Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis)
- Where
- 16 sites in Brazil, India and 6 more
- Volunteers
- 208 people
- Sponsor
- Janssen Infectious Diseases BVBA
Tuberculosis, COVID-19
Evaluating the Impact of Computer-assisted X-ray Diagnosis and Other Triage Tools to Optimise Xpert Orientated Community-based Active Case Finding for TB and COVID-19
Tuberculosis (TB) is now the commonest cause of death in many African countries. Globally, ~35% (almost 1 in 3) of TB cases are 'missed' (remain undiagnosed or undetected).
- Conditions
- Tuberculosis, COVID-19, HIV Infections
- Trial name
- NCT05220163
- Testing
- CAD, Xpert
- Where
- 3 sites in South Africa, Zambia and 1 more
- Volunteers
- 26,200 people, healthy volunteers welcome
- Sponsor
- University of Cape Town
HIV, AIDS
Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment
The purpose of this study is to evaluate and compare the efficacy of immediate antiretroviral therapy versus 2 month deferred anti-Tb therapy upon the clinical course of tuberculosis and HIV infection in patients with AIDS and…
- Conditions
- HIV, AIDS, Tuberculosis
- Trial name
- NCT00737724
- Testing
- Simultaneous ARV and antiMTB, Deferred RV and antiMTB treatment
- Where
- 2 sites in Mexico
- Volunteers
- 63 people
- Sponsor
- Instituto Nacional de Enfermedades Respiratorias
HIV Infection, Tuberculosis
Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV
There is a rapidly-growing need to identify evidence-based, safe, and effective co-treatment regimens for HIV-related tuberculosis (TB) among patients who require protease inhibitor (PI)-based antiretroviral therapy (ART).
- Trial name
- NCT01601626
- Testing
- Standard-dose Lopinavir/Ritonavir, Double-dose Lopinavir/Ritonavir, Raltegravir
- Where
- 9 sites in Brazil, Haiti and 3 more
- Volunteers
- 71 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Tuberculosis
Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of multiple doses of PNU-100480 given for 14 or 28 days.
- Trial name
- NCT00990990
- Testing
- PNU-100480, Linezolid
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Sequella, Inc.
Pulmonary TB
A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis
This trial will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of multiple oral doses of OPC-167832 in participants with uncomplicated, smear-positive, drug-susceptible pulmonary tuberculosis (TB).
- Trial name
- NCT03678688
- Testing
- 10 mg OPC-167832, 30 mg OPC-167832, 90 mg OPC-167832
- Where
- 3 sites in South Africa
- Volunteers
- 122 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Drug Susceptible Pulmonary Tuberculosis
Bactericidal Activity and Safety of Nicotinamide in Combination With Bedaquiline, Pretomanid, and Linezolid in Drug-susceptible Pulmonary Tuberculosis
The purpose of this study is to determine if nicotinamide in combination with bedaquiline, pretomanid, and linezolid, is safe and effective in treating drug-susceptible pulmonary tuberculosis.
- Trial name
- NCT07517445
- Testing
- Bedaquiline, pretomanid, linezolid, Nicotinamide (NAM)
- Where
- 4 sites in South Africa
- Volunteers
- 165 people
- Sponsor
- Gates Medical Research Institute
Active Tuberculosis
Characterization and Evaluation of Diagnostic Biomarkers for Tuberculosis
There was no sensitive and specific biomarker for tuberculosis infection, disease progression and predicting the prognosis of treatment.
- Trial name
- NCT01269268
- Where
- South Korea
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Tuberculosis
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
According to WHO, about 40% of the incident TB cases in 2020 are either under-reported or under-diagnosed causing on one hand major health risks and on the other hand catastrophic financial consequences.
- Trial name
- NCT05526885
- Testing
- CAD4TB, POC-CRP, Xpert MTB/RIF Ultra
- Where
- 2 sites in Lesotho, South Africa
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Klaus Reither
To Determine the Prevalence of Latent Tuberculosis in Each Group, To Monitor the Occurrence of Active Tuberculosis
Surveillance and Follow-up for Latent Tuberculosis Infection and Observation of the Effect of Prophylactic Latent Tuberculosis Treatment in Patients With Severe Chronic Kidney Disease or Receiving Long-term Dialysis
To follow-up the latent tuberculosis infection and evaluate the risk of developing active tuberculosis in patients with severe chronic kidney disease or receiving long-term dialysis
- Trial name
- NCT01685086
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- National Taiwan University Hospital
Immune Reconstitution Inflammatory Syndrome, HIV
Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone
Tuberculosis (TB) is the most common opportunistic infection amongst HIV-infected patients starting antiretroviral therapy (ART) in developing countries and thus the most frequent form of immune reconstitution inflammatory…
- Conditions
- Immune Reconstitution Inflammatory Syndrome, HIV, Tuberculosis
- Trial name
- Pred-ART (NCT01924286)
- Testing
- Prednisone
- Where
- South Africa
- Volunteers
- 240 people
- Sponsor
- University of Cape Town
Tuberculosis
Effects of Vitamin D Supplementation on Antimycobacterial Immunity
The purpose of this study is to determine how vitamin D supplementation (ergocalciferol) affects the immune response to mycobacterial infection.
- Trial name
- NCT00157066
- Testing
- Ergocalciferol
- Where
- United Kingdom
- Volunteers
- 230 people
- Sponsor
- Barts & The London NHS Trust
Pulmonary Tuberculosis
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (TMC207-CL001)
The trial will evaluate the extended bactericidal activity of 14 consecutive days of oral administration of TMC207 at multiple doses as determined by the rate of change of log10 colony forming units (CFU) per ml sputum over the…
- Trial name
- NCT01215110
- Testing
- TMC207, Rifafour e-275 mg
- Where
- South Africa
- Volunteers
- 68 people
- Sponsor
- Global Alliance for TB Drug Development
Tuberculosis
Assessing the Ability of the T-SPOT®.TB Test (IQ)
The primary objective of this clinical research study is to demonstrate performance of the normalized TB specific lymphocyte response (NTBSLR) in identifying patients with active TB disease.
- Trial name
- IQ (NCT03973970)
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Oxford Immunotec
Tuberculosis
Randomized Clinical Trial: IS Zinc and Zinc Ionophere EGCG as Supplement Improve Outcome of Active Pulmonary Tuberculosis
Tuberculosis is still global burden disease at all the word and effect on quality life of patients and affect on health authorities because the cost of medicine and health cost .
- Trial name
- NCT05116098
- Testing
- zinc 50 mg + Epigallocatechin gallate
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ministry of Health, Saudi Arabia
To Compare the Serum Apoptosis-associated Markers Between Patients With Active TB and Patients With LTBI, To Evaluate the Efficiency of Apoptosis-associated Markers to Differentiate Potential of Active TB From LTBI
The Role of Apoptosis Associated Markers in Pathogenesis of Pulmonary Tuberculosis
To compare the serum apoptosis-associated markers between patients with active TB and patients with LTBI To evaluate the efficiency of apoptosis-associated markers to differentiate potential of active TB from LTBI
- Trial name
- NCT01676155
- Where
- Taiwan
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital